A recent survey of clinicians in England showed that 47% of them favored the use of statins for treating patients at risk for developing cognitive impairment and dementia due to vascular risk factors according to a new study published in the Journal of Neurological Sciences (March 2005; 229-230: 147-150). For pharmacists, while generic atorvastatin may be a boon Atorvastatin lipitor patent for pharmacy margins, the transfer of $7. 4 billion from the branded drug market to the generics arena would spell a significant downturn in same-store pharmacy sales. NEW YORK — Pfizer Inc. Edwards & Atorvastatin lipitor patent sons Inc. , notes that the case isn’t the only issue facing Lipitor. Ruling) is atorvastatin lipitor patent a nice psychological boost, but you can’t extrapolate the U. The patent (EP 409,281) had atorvastatin lipitor patent been challenged by generics manufacturer Ranbaxy and expires in July 2010. For the nine Atorvastatin lipitor patent months ended September, Lipitor generated $5. 3 billion in U. With its 2003 launch of Crestor and clinical claims that Crestor works as well as Lipitor–if not atorvastatin lipitor patent better–in lowering low-density lipoproteins, there is a strong possibility Crestor could become the most-prescribed prescription statin on the market. The enantiomer patent expires in July 2010. Analyst Timothy Anderson wrote that Wall Street is divided on how the U. NEW YORK — Pfizer Inc said today that the Federal Patent Court in Munich, Germany has revoked the company’s patent covering atorvastatin calcium, the active ingredient in Lipitor. In October, a British court ruled one of Pfizer’s atorvastatin lipitor patent british patents on Lipitor invalid, although it upheld another. Cinfa, Kern, Alter atorvastatin lipitor patent and Belmac can seek to appeal the decision to the Supreme Court of Spain. MAYWOOD, N. The decision prevents Ranbaxy from launching its drug before Lipitor’s basic patent (EP 247,633) expires in November 2011. Pfizer shares atorvastatin lipitor patent rose 54 cents, or 2. 2 percent to close at $24. 84 on the New York atorvastatin lipitor patent stock Exchange. The New York-based company said it would appeal the decision on the second patent, which expires in July 2010 and covers the calcium salt of atorvastatin. In addition to recent studies presented at major medical conferences, published peer-reviewed studies include, for example, International Journal of Geriatric Psychiatry 2004; 19:327-32; Neuroepidemiology 2004; 23:94-8; Neuron 2004; 41:7-10; Arch Neurol 2000; 57:1439-1443; Lancet 2000; 356:1627-1631; Arch Neurol 2002; 59:223-227; J Gerontol Biol Sci Med Sci 2002;57:M414-M418; and J Am Geriatr Soc 2002;50:1852-1856. A ruling Atorvastatin lipitor patent is anticipated by the end of the year. Ranbaxy has brought a suit against two Lipitor patents in the United States, where $6. 6 billion, or about 61 atorvastatin lipitor patent percent, of the drug’s sales are generated.